Compugen Ltd., a renowned clinical-stage therapeutic discovery and development company, has announced its research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline includes COM701, an anti-PVRIG antibody, which is currently in Phase I clinical trial for solid tumors treatment. COM902, a therapeutic antibody targeting TIGIT, is also being tested in a Phase I monotherapy clinical study in patients with advanced malignancies. In addition, Bapotulimab, a therapeutic antibody treating ILDR2, is undergoing a Phase I clinical study for patients with naive head and neck squamous cell carcinoma, and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, is currently in Phase II clinical study to treat advanced or metastatic non-small cell lung cancer. Furthermore, the company's therapeutic pipeline also includes early-stage immuno-oncology programs that aim to address various mechanisms of immune resistance. COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is another program of Compugen's therapeutic pipeline. Compugen has signed a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators. Additionally, the company has also joined forces with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. In partnership with Johns Hopkins School of Medicine, Compugen will evaluate novel T cell and myeloid checkpoint targets. Moreover, Compugen has a license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products and a research collaboration agreement with Johns Hopkins University for myeloid. Founded in 1993 and headquartered in Holon, Israel, Compugen Ltd. continues to advance its research and development of breakthrough therapies to combat various diseases.
Compugen Ltd. 's ticker is CGEN
The company's shares trade on the NASDAQ stock exchange
They are based in Holon, Israel
There are 51-200 employees working at Compugen Ltd.
It is https://www.cgen.com/
Compugen Ltd. is in the Healthcare sector
Compugen Ltd. is in the Biotechnology industry
The following five companies are Compugen Ltd. 's industry peers: